Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed colorectal or appendiceal cancer
• •* Stage IV disease
• •* Peritoneal surface dissemination of disease (peritoneal carcinomatosis)
• •Measurable disease according to RECIST criteria
• •No active CNS metastases
• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-2
• •Absolute neutrophil count ≥ 1,500/mm³
• •Platelet count ≥ 100,000/mm³
• •Creatinine ≤ 1.5 mg/dL OR creatinine clearance \> 60 mL/min
• •Bilirubin ≤ 1.5 mg/dL
• •Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)
• •AST and ALT ≤ 3 times ULN
• •No active infection or fever ≥ 101.3°F within the past 3 days
• •No other malignancy within the past 5 years except curatively treated basal cell skin cancer, cervical intra-epithelial neoplasia, or localized prostate cancer with a current prostate-specific antigen of \< 1.0 mg/dL on 2 successive evaluations, ≥ 3 months apart, with the last evaluation within the past 4 weeks
• •No peripheral neuropathy ≥ grade 2
• •No other medical condition, mental illness, or substance abuse that, in the opinion of the principal investigator, would preclude study compliance
• •No known hypersensitivity to any component of oxaliplatin
• •No known HIV positivity
• •No hepatitis B or C positivity (active, previously treated, or both)
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients and their partners must use effective contraception during and for 90 days after completion of study treatment
• •PRIOR CONCURRENT THERAPY:
• •Recovered from prior surgery, radiotherapy, and other anticancer therapies
• •More than 30 days since prior and no other concurrent investigational therapy
• •No prior radiotherapy to \> 25% of bone marrow
• •No prior allogeneic stem cell transplantation
• •No concurrent antiretroviral therapy